Dr. Chari on Avenues for Future Research in Newly Diagnosed Multiple Myeloma
Ajay Chari, MD, discusses several avenues for future study in newly diagnosed multiple myeloma.
Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1
Dr Ajay Chari reviews the results from the MonumenTAL-1 trial which evaluates the use of talquetamab, a GPRC5D x CD3 bispecific antibody in patients with relapsed refractory multiple myeloma.
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Both Gastric and Breast HER2 Scoring Algorithms Applicable in mCRC Testing
Encorafenib Plus Cetuximab and Chemotherapy Demonstrates Safety, Efficacy in BRAF V600E–Mutant mCRC
2 Clarke Drive Cranbury, NJ 08512